| scholarly article | Q13442814 |
| P50 | author | Magne Børset | Q39185277 |
| P2093 | author name string | A Waage | |
| A Sundan | |||
| U M Fagerli | |||
| B Stordal | |||
| K F Wader | |||
| R U Holt | |||
| P2860 | cites work | Role of hepatocyte growth factor activator (HGF activator) in invasive growth of human glioblastoma cells in vivo. | Q40384156 |
| Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor | Q40436931 | ||
| A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells | Q40505746 | ||
| Emerging multipotent aspects of hepatocyte growth factor | Q41066829 | ||
| Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma | Q42496244 | ||
| Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer | Q46590851 | ||
| The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. | Q47982958 | ||
| Guidelines on the diagnosis and management of multiple myeloma 2005. | Q53556535 | ||
| Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator | Q72221318 | ||
| Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group | Q74106121 | ||
| Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma | Q77748034 | ||
| Activation of the zymogen of hepatocyte growth factor activator by thrombin | Q24318554 | ||
| Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor | Q24555664 | ||
| Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII | Q28115845 | ||
| Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease | Q28144714 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator | Q34323936 | ||
| Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. | Q34454578 | ||
| Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor | Q35144580 | ||
| HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. | Q38307158 | ||
| Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. | Q38507554 | ||
| Hepatocyte growth factor promotes migration of human myeloma cells | Q40004768 | ||
| Activation of hepatocyte growth factor activator zymogen (pro-HGFA) by human kallikrein 1-related peptidases. | Q40020532 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 380-383 | |
| P577 | publication date | 2008-08-06 | |
| P1433 | published in | European Journal of Haematology | Q15765799 |
| P1476 | title | Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma | |
| P478 | volume | 81 |
| Q84358736 | A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS |
| Q33514848 | A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation |
| Q38588911 | Bone morphogenetic protein-9 suppresses growth of myeloma cells by signaling through ALK2 but is inhibited by endoglin. |
| Q57066901 | Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review |
| Q61795626 | Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth |
| Q34501627 | In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib |
| Q38255480 | Mechanisms of hepatocyte growth factor activation in cancer tissues |
| Q42400150 | Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma |
| Q33168449 | Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. |
| Q50985091 | Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment |
| Q38008379 | Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes |
Search more.